Kymera Therapeutics, Inc. - Common Stock, $0.0001 par value per share (KYMR)

Historical Holders from Q3 2020 to Q3 2025

Symbol
KYMR on Nasdaq
Type / Class
Equity / Common Stock, $0.0001 par value per share
Shares outstanding
80.8M
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
80.9M
Holdings value
$4.58B
% of all portfolios
0.003%
Grand Portfolio weight change
+0%
Number of holders
206
Number of buys
116
Number of sells
-92
Average Value change %
0%
Average buys %
+0.001%
Average sells %
-0.002%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Kymera Therapeutics, Inc. - Common Stock, $0.0001 par value per share (KYMR)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BAKER BROS. ADVISORS LP 10.9% +14% $551M $128M 8.68M +30.2% Baker Bros. Advisors LP 09 Dec 2025
BIOTECHNOLOGY VALUE FUND L P 8.5% $436M 6.87M BVF PARTNERS L P/IL 11 Dec 2025
FMR LLC 8.2% +20% $333M $83.2M 5.88M +33.3% FMR LLC 30 Sep 2025
WELLINGTON MANAGEMENT GROUP LLP 7.7% -16.7% $241M -$28M 5.37M -10.4% Wellington Management Group LLP 30 Jun 2025
VANGUARD GROUP INC 8.05% $174M 5.23M The Vanguard Group 31 Mar 2025
PRICE T ROWE ASSOCIATES INC /MD/ 7.1% $289M 5.1M T. Rowe Price Associates, Inc. 30 Sep 2025
BlackRock, Inc. 5.4% $166M 3.8M BlackRock, Inc. 30 Jun 2025

Institutional Holders of Kymera Therapeutics, Inc. - Common Stock, $0.0001 par value per share (KYMR)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 80.9M $4.58B +$138M $56.60 206
2025 Q2 78.8M $3.44B +$271M $43.64 208
2025 Q1 72.8M $2B +$5.35M $27.37 171
2024 Q4 71.7M $2.89B +$14.4M $40.23 177
2024 Q3 69.1M $3.27B +$183K $47.33 174
2024 Q2 67.4M $2.01B +$5.55M $29.85 153
2024 Q1 67.2M $2.7B +$297M $40.20 161
2023 Q4 60.5M $1.54B +$89M $25.46 134
2023 Q3 57.4M $797M -$18.2M $13.90 120
2023 Q2 58.2M $1.34B +$29.1M $22.99 124
2023 Q1 56.9M $1.68B +$23.1M $29.63 123
2022 Q4 56.2M $1.4B +$98.5M $24.96 116
2022 Q3 52.9M $1.15B +$29.2M $21.77 119
2022 Q2 49.4M $974M +$16.5M $19.69 99
2022 Q1 45.7M $1.93B +$62.4M $42.32 124
2021 Q4 43M $2.73B +$129M $63.49 123
2021 Q3 34.6M $2.04B +$492M $58.74 115
2021 Q2 26.5M $1.28B +$188M $48.50 109
2021 Q1 22.2M $862M +$92.7M $38.86 94
2020 Q4 20.3M $1.25B +$53M $62.00 74
2020 Q3 16.8M $543M +$543M $32.31 51